Newsletter January 2018

*|MC:SUBJECT|*
Toxys Newsletter January 2018
View this email in your browser
Toxys logo
Best Wishes for 2018

Toxys would like to wish you an innovative and successful 2018. This year is going to be a very exiting year for Toxys, we will finalise our validation study and publish the results. Also mayor development of ReproTracker and Toxplot are expected. We look forwards to sharing these developments with you and hope our paths may cross this year! 

Best regards, 
The Toxys Team

Toxys and Omnigen receive MIT grant to develop Toxplot software for animal-free chemical safety testing.

4 January 2018 - Toxys and Omnigen have received a MIT grant for the development and extension of the ToxPlot software. With this grant, the ToxPlot analysis tool will be further developed to allow quantitative and hypothesis-free toxicity profiling of novel chemicals. With the MIT grant, Toxplot will be further developed into a software platform that can be used by toxicology laboratories in the pharmaceutical, chemical and cosmetics industry. 



ToxTracker is Toxys’ unique animal-free test system for identification of potentially carcinogenic properties of novel chemicals. ToxTracker combines multiple biomarkers to get mechanistic insight into the of action of (geno)toxic compounds. The assay not only includes markers for DNA damage, but also for a non-genotoxic mode of action, including oxidative stress, protein misfolding and cytotoxicity. The combination of multiple biomarkers results in a rich dataset and an extensive toxicological profile of the tested compounds tested.

New developments for ToxPlot:

  • ToxPlot analysis tools for hypothesis-free data mining and analysis of the rich datasets obtained by ToxTracker.
  • A ToxTracker database containing extensive (geno)toxicity data from a large set of reference compounds. 
  • Quantitative modelling and visualisation modules for quantitative analysis of the toxic properties of compounds to improve human risk assessment. 


Read more on the grant and scheduled developments

ToxTracker workshop at the SOT meeting 2018

You are cordially invited to join the first official ToxTracker workshop during the SOT2018 meeting in San Antonio. The workshop provides an unique opportinuty to learn everything you want to know about the ToxTracker reporter assay. We will update you on the latest developments around ToxTracker and its applications. You can hear about the experiences from ToxTracker users and ask your questions about how ToxTracker can be valuable for you.

The workshop will be on the 13th of March starting at 6.00 pm. We will send more information on the program in a separate mail, but please add this meeting in your agenda if you will join the SOT. 

News in short
New publication on ToxTracker
Genotoxic and mutagenic properties of Ni and NiO nanoparticles investigated by comet assay, γ-H2AX staining, Hprt mutation assay and ToxTracker reporter cell lines -  2017 Dec 15. doi: 10.1002/em.22163. 

Validation study in next phase
All of the 8 participating laboratories have installed the ToxTracker assay in their laboratory. The first set of compounds have been tested in the laboratories to determine the proficiency of the labs. In the next phase a large set of compounds will be tested. We expect to finalise the study in the summer of 2018. 
Opportunities to get in contact
We will attend and give presentations at several conferences this year. We are more than happy to meet alongside any of these meetings. If you are interested to learn more about our unique assays we could also schedule a TC to take you to a presentation on the assay.

Meetings we will attend: 
- SOT 11-15 March 2018 - booth #1745
- EEMGS/GUM 18-21 March 2018
- GTA 2-4 May 2018
- UKEMS 2-5 September 2018
- Eurotox 2-5 September 2018 

Please contact me if there are any questions: 
Paula van Rossum 
Director Business Development & Sales
p.vanrossum@toxys.com
+31 - 71 - 3322470


 
Learn more about our unique services
LinkedIn
LinkedIn
Twitter
Twitter
Website
Website
Copyright © 2015 Toxys B.V., All rights reserved.
Please visit our website for more information






This email was sent to *|EMAIL|*
why did I get this?    unsubscribe from this list    update subscription preferences
*|LIST:ADDRESSLINE|*